ARPA-H selected innovation teams in June 2026 for the ADVOCATE program, a three-year federally funded effort to build the ...

The FDA approved orforglipron (Foundayo) on April 1, 2026, making it the first non-peptide oral GLP-1 receptor agonist ...

A University of Calgary study published in Science Advances this month found that chronic wasting disease can spread silently ...

In this single-group, open-label trial, olorofim was associated with a complete or partial clinical response in over 75% of ...

Advanced Medical Care at Home Among Patients With Acute Heart Failure 1. Following hospitalization for acute decompensated ...

Adults who received cryoanalgesia during minimally invasive thoracic surgery experienced higher neuropathic pain scores at ...

Erector spinae plane blocks reduced PACU opioid requirements and modestly shortened PACU stay, but did not produce a ...

Duodenal-jejunal bypass liners were superior to sham in reducing HbA1c and improved weight loss in patients with uncontrolled type 2 diabetes mellitus. 2. Despite efficacious outcomes, ...

Chemotherapy appears to be independently associated with reduced pain severity in advanced pancreatic cancer, reinforcing the ...

Although neurological symptoms (motor deficits, sensory impairment) were more frequent in patients with sitting-related ...

In this cross-sectional study, one-third of federally qualified health centers (FQHCs) in the United States did not provide onsite prenatal care and instead referred pregnant patients to external ...

In this target trial emulation, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with a small increase ...